Mototsugu Shimokawa - Concepedia

Author

Mototsugu Shimokawa

National Hospital Organization Kyushu Cancer Center ORCID

Also Known As

Komoda, Masato, M. Shimokawa, M., Shimokawa, MOTOTSUGU SHIMOKAWA, Mototsugu SHIMOKAWA, Mototsugu Shimokawa, Seiichi Morokuma, Shimokawa M, Shimokawa Mototsugu, Shimokawa, M.

570

Publications

6.1K

Citations

H-Index

Concepts

All Affiliations

National Hospital Organization Kyushu Cancer Center Kyushu University Yamaguchi University National Kyushu Medical Center Kurume University

About

Mototsugu Shimokawa is an author at National Hospital Organization Kyushu Cancer Center specializing in medicine, oncology, and lung cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	31	67	2.6K
2	Health Sciences	8	8	344
3	Engineering	2	2	128
4	Anatomy	1	1	86
5	Biomedical Engineering	1	1	42

Mototsugu Shimokawa

159

Publications

5.1K

Citations

H-Index

Page 1

	Year	Citations
Treatment and survival among 1594 patients with ATL Hiroo Katsuya, Kenji Ishitsuka, Atae Utsunomiya, Blood	2015	302
Clinical Significance of PD-L1 Protein Expression in Surgically Resected Primary Lung Adenocarcinoma Kazuki Takada, Tatsuro Okamoto, Fumihiro Shoji, Journal of Thoracic Oncology Tumor BiologyMedicineImmunologyPathologyBronchial Neoplasm	2016	185
Computed tomography features of resected lung adenocarcinomas with spread through air spaces Gouji Toyokawa, Yuichi Yamada, Tetsuzo Tagawa, Journal of Thoracic and Cardiovascular Surgery Computed TomographyResected Lung AdenocarcinomasMedical ImagingAir SpacesTomography Features	2018	107
Re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab (KSCC1604) Hiroshi Saeki, Eiji Oki, Tomomi Kashiwada, European Journal of Cancer Her2 StatusSurgical OncologyOncologyGastrointestinal OncologyCancer Management	2018	97
Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer Hiroshige Yoshioka, Mototsugu Shimokawa, Takashi Seto, Annals of Oncology	2019	89
A new method for measurement of placental elasticity: Acoustic radiation force impulse imaging Maiko Sugitani, Yasuyuki Fujita, Yasuo Yumoto, Placenta Obstetric ImagingMedical UltrasoundEngineeringMedical ImagingPlacental Elasticity	2013	86
Clinical impact of probiotics on the efficacy of <scp>anti‐PD</scp>‐1 monotherapy in patients with nonsmall cell lung cancer: A multicenter retrospective survival analysis study with inverse probability of treatment weighting Kazuki Takada, Mototsugu Shimokawa, Shinkichi Takamori, International Journal of Cancer ProbioticTreatment WeightingCell Lung CancerMedicineCancer Management	2021	85
Efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting with a moderately emetogenic chemotherapy regimen: a multicenter, placebo-controlled, double-blind, randomized study in patients with gynecologic cancer receiving paclitaxel and carboplatin Hideaki Yahata, Hiroaki Kobayashi, Kenzo Sonoda, International Journal of Clinical Oncology OncologyChemotherapy-induced NauseaEmetogenic Chemotherapy RegimenCancer ManagementPharmacology	2015	82
Prognostic impact of controlling nutritional status score in resected lung squamous cell carcinoma Gouji Toyokawa, Yuka Kozuma, Taichi Matsubara, Journal of Thoracic Disease	2017	80
Role of surgical resection for patients with limited disease-small cell lung cancer Tomoyoshi Takenaka, Mitsuhiro Takenoyama, Eiko Inamasu, Lung Cancer Surgical OncologySurgical ResectionMedicineBronchial NeoplasmThoracic Surgery	2015	78

Page 1